Sanofi, Regeneron Begin Phase 3 Study For Eczema Drug Dupilumab

By RTT News, October 20, 2014, 02:16:00 AM EDT

(RTTNews.com) - Sanofi (SNY, SAN) and Regeneron Pharmaceuticals, Inc. ( REGN ) Monday announced the start of the phase 3 trial for dupilumab on patients with atopic dermatitis or eczema.

Primary objective of Liberty Ad Chronos, first trial of the phase 3 study, is to demonstrate the efficacy of the drug in adults with moderate to severe AD, when administered concomitantly with topical corticosteroids through 16 weeks, the companies said. The trial will have around 700 patients.

Secondary objective is to gauge the safety and efficacy of dupilumab up to 52 weeks.

"This Phase 3 program will evaluate if blocking IL-4 and IL-13, two key cytokines in the Th2 inflammatory pathway, may provide a potential new approach for this chronic, difficult-to-manage disease," said Donald Leung, a member of the Liberty Ad Clinical Trials Steering Committee.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Here is the original post:
Sanofi, Regeneron Begin Phase 3 Study For Eczema Drug Dupilumab